Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Atopic Dermatitis | Emerging Therapies | Dupixent (dupilumab) | US | Wave 2 | 2017

Login to access report north_east
Contact sales account_box

Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary research data collected 1, 6, and 12 months after Dupixent’s launch. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial, adoption, and use, including anticipated future trends, of Dupixent. We also explore Sanofi/Regeneron’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What are U.S. dermatologists’ awareness of and familiarity with Dupixent, and what are their perceptions of the product?
  • To which patients are prescribers of Dupixent prescribing the product, what are their reasons for prescribing it, and how satisfied are they with it?
  • What promotional messages and activities are Sanofi and Regeneron using to support Dupixent’s launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How do the trial and adoption of Dupixent compare with other recent product launches for AD?

Methodology: ~75-100 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Dupixent

Key companies: Sanofi/Regeneron

Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
north_east
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
north_east
Report
Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east